Neuroprotective Potential of Caffeic Acid Phenethyl Ester (CAPE) in CNS Disorders: Mechanistic and Therapeutic Insights
Open Access
- 1 September 2021
- journal article
- review article
- Published by Bentham Science Publishers Ltd. in Current Neuropharmacology
- Vol. 19 (9) , 1401-1415
Abstract
Neurological disorders like Alzheimer’s disease (AD), Parkinson’s disease (PD), stroke, amyotrophic lateral sclerosis (ALS), Huntington’s disease (HD), epilepsy, traumatic brain injury (TBI), depression, and anxiety are responsible for thousands of deaths worldwide every year. With the increase in life expectancy, there has been a rise in the prevalence of these disorders. Age is one of the major risk factors for these neurological disorders, and with the aged population set to rise to 1.25 billion by 2050, there is a growing concern to look for new therapeutic molecules to treat age-related diseases. Caffeic acid phenethyl ester (CAPE) is a molecule obtained from a number of botanical sources, such as the bark of conifer trees as well as propolis which is extracted from beehives. Though CAPE remains relatively unexplored in human trials, it possesses antioxidant, anti-inflammatory, antimitogenic, and anti-cancer activities, as shown by preclinical studies. Apart from this, it also exhibits tremendous potential for the treatment of neurological disorders through the modulation of multiple molecular pathways and attenuation of behavioural deficits. In the present article, we have reviewed the therapeutic potential of CAPE and its mechanisms in the treatment of neurological disorders.Keywords
Funding Information
- Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, India (2019-2020-NPLC-SSSHARMA)
This publication has 89 references indexed in Scilit:
- Caffeic Acid Phenethyl Ester Protects Blood–Brain Barrier Integrity and Reduces Contusion Volume in Rodent Models of Traumatic Brain InjuryJournal of Neurotrauma, 2012
- Caffeic acid phenethyl ester protects nigral dopaminergic neurons via dual mechanisms involving haem oxygenase‐1 and brain‐derived neurotrophic factorBritish Journal of Pharmacology, 2012
- The Science of Stroke: Mechanisms in Search of TreatmentsNeuron, 2010
- An in vitro screening cascade to identify neuroprotective antioxidants in ALSFree Radical Biology and Medicine, 2009
- Progressive familial intrahepatic cholestasisOrphanet Journal of Rare Diseases, 2009
- Neuroprotective effects of NU1025, a PARP inhibitor in cerebral ischemia are mediated through reduction in NAD depletion and DNA fragmentationLife Sciences, 2006
- Mechanisms of Neuropathic PainNeuron, 2006
- Caffeic acid phenethyl ester blocks free radical generation and 6-hydroxydopamine-induced neurotoxicityLife Sciences, 2006
- Caffeic acid phenethyl ester ameliorates cerebral infarction in rats subjected to focal cerebral ischemiaLife Sciences, 2006
- Huntingtons DiseaseNew England Journal of Medicine, 1986